These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26639960)

  • 21. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI.
    Ding X; Charnigo RJ; Schmitt FA; Kryscio RJ; Abner EL;
    PLoS One; 2019; 14(2):e0212435. PubMed ID: 30802256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information.
    Steenland K; Zhao L; John SE; Goldstein FC; Levey A; Alvaro A;
    J Alzheimers Dis; 2018; 63(4):1383-1393. PubMed ID: 29843232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
    Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
    J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.
    Cloutier S; Chertkow H; Kergoat MJ; Gauthier S; Belleville S
    J Alzheimers Dis; 2015; 47(4):901-13. PubMed ID: 26401770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
    de Mauléon A; Soto M; Kiyasova V; Delrieu J; Guignot I; Galtier S; Lilamand M; Cantet C; Lala F; Sastre N; Andrieu S; Pueyo M; Ousset PJ; Vellas B
    J Prev Alzheimers Dis; 2017; 4(3):183-193. PubMed ID: 29182709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
    Trzepacz PT; Hochstetler H; Yu P; Castelluccio P; Witte MM; Dell'Agnello G; Degenhardt EK;
    Dement Geriatr Cogn Disord; 2016; 41(1-2):68-79. PubMed ID: 26625159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study.
    Wang YL; Chen W; Cai WJ; Hu H; Xu W; Wang ZT; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2020; 73(2):759-768. PubMed ID: 31839612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.
    Caldwell JZK; Berg JL; Cummings JL; Banks SJ;
    Alzheimers Res Ther; 2017 Sep; 9(1):72. PubMed ID: 28899422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of the Spanish version of the Everyday Cognition scale in the diagnosis of mild cognitive impairment and mild dementia in an older cohort from the Argentina-ADNI.
    Russo MJ; Cohen G; Chrem Mendez P; Campos J; Martín ME; Clarens MF; Tapajoz F; Harris P; Sevlever G; Allegri RF
    Aging Clin Exp Res; 2018 Oct; 30(10):1167-1176. PubMed ID: 29380265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.
    Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Machulda M; Lowe VJ; Mielke MM; Roberts RO; Gunter JL; Senjem ML; Geda YE; Rocca WA; Petersen RC; Jack CR
    Neurology; 2016 Mar; 86(12):1128-35. PubMed ID: 26911640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.